This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Astex Pharmaceuticals' CEO Discusses Q4 2011 Results - Earnings Call Transcript

Stocks in this article: ASTX

Astex Pharmaceuticals (ASTX)

Q4 2011 Earnings Call

March 05, 2012 4:30 pm ET

Executives

Timothy L. Enns - Senior Vice President of Investor Relations, Business Development & Corporate Communications, Senior Vice President of Corporate Communications & Business Development and Vice President of Business Development

James S. J. Manuso - Chairman of the Board and Chief Executive Officer

Michael Molkentin - Chief Financial Officer, Principal Accounting Officer and Corporate Secretary

Robert Corringham -

Harren Jhoti - Founder, Chief Executive officer and Director

Analysts

Boris Peaker - Oppenheimer & Co. Inc., Research Division

Thomas Yip - McNicoll, Lewis & Vlak LLC, Research Division

Robin Davison - Edison Investment Research Limited

Presentation

Operator

Good day, ladies and gentlemen, and thank you for standing by, and welcome to the Astex Pharmaceuticals Fourth Quarter and Year End 2011 Earnings Conference Call. [Operator Instructions] As a reminder, this conference may be recorded. And now it's my pleasure to turn the call over to Timothy Enns, Senior Vice President, Corporate Communications and Marketing. Sir, the floor is yours.

Timothy L. Enns

Thank you, operator. Good day and thank you for joining us for Astex Pharmaceuticals 2011 Fourth Quarter and Annual Financial Results conference call. With me today are Dr. James Manuso, Chairman and Chief Executive Officer; Dr. Harren Jhoti, President and member of the Board of Directors; Dr. Martin Buckland, Chief Business Officer; Michael Molkentin, Chief Financial Officer; Dr. Robert Corringham, Vice President of Clinical Development; and Dr. David Smith, Vice President of Regulatory and Quality Affairs.

In a few moments, Jim Manuso and Michael Molkentin will deliver remarks on the 2011 fourth quarter and fiscal year financial results and our business outlook for 2012. After prepared comments, we will open the line for questions. Earlier today, we issued a press release with our financial results. A copy of the press release is available in the Investor Relations section of our website at www.astx.com. In addition, this call is being webcast and may be accessed via the Investor Relations section of our website. A webcast replay will be available for 30 days.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,387.21 -291.49 -1.65%
S&P 500 2,029.55 -27.54 -1.34%
NASDAQ 4,681.4970 -90.2660 -1.89%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs